Questions? Chat with the founder on WhatsApp

Chat with the founder on WhatsApp
Arthneeti
HomeRankingsIPOScreenerInstitutions
HomeRankingsIPOScreenerInstitutions
OSEL Devices LtdQ4 FY26Healthcare Equipment & Supplies
Home/Stocks/OSEL Devices Ltd/Q4 FY26

OSEL Devices Ltd Q4 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹422P/E: 25.4Market Cap: ₹743 CrSector: Healthcare Equipment & Supplies

Management growth scorecard

Revenue

Category 1

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 1
  • →OSEL expects continued positive growth in sales and revenue for the next few years, maintaining or exceeding recent growth rates.
  • →Mobile sales (feature phones) are stable at 60,000-70,000 units monthly, with volumes expected to rise, especially during festivals.
  • →FY26 mobile sales amounted to around INR55 crores in H2, with an overall FY26 revenue close to INR300 crores; FY27 target is to surpass INR500 crores.
  • →Smartphone manufacturing recently started and is expanding, branded under Philips, with expectations of higher contributions to the top line.
  • →Export sales target is INR50 crores for the current year, up from INR23 crores last year.
  • →The manufacturing hub at JNPA (Navi Mumbai) will enhance export capabilities and revenues.
  • →Entry into retail hearing aid business via SFL acquisition is expected to improve margins and revenue starting FY27.
  • →Overall, the company targets both volume growth and improved profitability across segments.

Margin guidance

Category 3
  • →OSEL Devices expects to maintain or exceed the growth achieved in FY26, with positive outlook for at least the next few years.
  • →Management targets continued growth in top line and EBITDA margins through expansion in all three verticals: mobile phones, hearing aids, and LED.
  • →The JNPA SEZ manufacturing and logistics hub (commercialization from April 2027) is expected to boost exports and contribute to higher revenue and margins.
  • →Hearing aids retail business via SFL acquisition is anticipated to enhance margins substantially, potentially doubling or tripling current profitability in that segment.
  • →Export sales are projected to increase to INR50 crores in FY27 from INR23 crores previously.
  • →Mobile sales are growing steadily, with feature phones at 60,000+ units/month and smartphones recently launched, contributing to revenue growth.
  • →PAT growth was 45.7% in FY26; management is optimistic about sustaining or improving profitability and EPS in coming years.

3 more insights locked — sign up free to unlock

Fundraise plans

  • →There is no explicit mention of any immediate or planned new fundraising through debt or equity in the call.
  • →The company has recently raised funds via IPO which were initially parked in mutual funds and utilized through working capital limits (Page 3).
  • →They are working on improving working capital utilization and reducing interest costs by converting cash credit into letters of credit and other arrangements (Page 4).
  • →They have received an LOI for a new manufacturing hub project (JNPA) which will require capex; however, exact funding details and amounts are not finalized yet (Page 4).
  • →Management plans to focus on improving operations and financial controls with a strengthened team, which may reduce the need for excessive borrowing (Page 10).
  • →No clear indication of new equity fundraises was provided in the transcript.

Order book

  • →No specific mention of a quantified current order book or pending orders in the transcript.
  • →The company has a sizable ongoing engagement in the defense segment with clients such as IMA Military Academy, Naval Academy, Air Force, DRDO, and ISRO.
  • →Growth in defense orders is expected with the onboarding of Captain Vivek, who is actively engaging with defense clients.
  • →The company received an LOI for the JNPA manufacturing hub project and is working on its implementation, which will add to order inflows.
  • →They have ongoing OEM LED manufacturing orders for big brands.
  • →Export orders are growing, with INR23 crores done last year and a target of INR50 crores this year.
  • →Mobile phone sales are stable with 60,000+ feature phones sold monthly and growth expected.
  • →Hearing aids and retail sales through the SFL acquisition are expected to increase orders going forward.

Capex plans

Yes
- OSEL Devices has planned a capital expenditure project for setting up a manufacturing hub at JNPA (Jawaharlal Nehru Port Authority) in Navi Mumbai. - The facility will operate as a Special Economic Zone (SEZ) focusing mainly on LED business, targeting international markets like North America, the Middle East, and Africa. - This hub will offer tax advantages, no import duties, and logistic benefits due to its strategic port location. - The company has recently received the Letter of Intent (LOI) for this project and is currently working on project planning. - Exact capex amount and timelines will be clarified once the project plan is finalized. - Future capex depends on this JNPA project primarily; no other specific capex plans were mentioned. - The company aims to transition some manufacturing locally to leverage "China plus one" strategy and improve cost competitiveness. This project is expected to add significant revenue and margin benefits once operational.

How does OSEL Devices Ltd rank vs peers in Healthcare Equipment & Supplies?

Pro feature
1OSEL Devices Ltd
Rev 1Mar 3
2Healthcare Equipment & Supplies Company A
Rev 1Mar 2
3Healthcare Equipment & Supplies Company B
Rev 2Mar 1
4Healthcare Equipment & Supplies Company C
Rev 2Mar 3

See full Healthcare Equipment & Supplies sector rankings

How does OSEL Devices Ltd rank in Healthcare Equipment & Supplies?

Compare OSEL Devices Ltd against every Healthcare Equipment & Supplies company (Q4 FY26) on revenue, margins and earnings-call signals.

View Healthcare Equipment & Supplies leaderboard →

Related research

Other quarters — OSEL Devices Ltd

Q2 FY26Q4 FY25

Healthcare Equipment & Supplies peers

Fischer Medical · Q2 FY26Poly Medicure · Q1 FY27Prevest Denpro Ltd · Q1 FY27Tarsons Products · Q1 FY27Vaidya Sane · Q2 FY26
OSEL Devices Ltd full stock analysisHealthcare Equipment & Supplies sectorEarnings call directoryRankings dashboard

Questions about this analysis? Chat directly with the founder — real answers about the research, not a support bot.

WhatsApp the founder

Research team or advisory firm? Get earnings-call intelligence and ranking history as research inputs for your firm.

For Institutions

Arthneeti AI

AI-powered stock analysis from earnings call transcripts. Helping Indian investors make smarter decisions with data-driven insights.

Analysis

  • Stock Rankings
  • Sectors
  • Compare Stocks
  • IPO Dashboard
  • Stock Screener
  • Earnings Call Analysis
  • Stocks Under ₹500
  • Multibaggers

Tools

  • MF Overlap Checker
  • SIP Calculator
  • CAGR Calculator
  • FD vs Equity
  • All Calculators

Resources

  • Blog
  • Weekly Digest
  • Portfolio Analysis
  • Build Portfolio
  • Earnings Calendar
  • Q1 FY27 Earnings Hub

Company

  • Pricing
  • How Our Analysis Works
  • For Institutions
  • Terms of Service
  • Privacy Policy

Compare

  • vs Screener.in
  • vs Trendlyne
  • vs Tickertape
  • vs Moneycontrol Pro
+91 90841 32575 support@arthneeti.com Bengaluru, India

© 2026 Arthneeti AI. All rights reserved.

AI-analyzed data from 1,500+ company earnings calls

Continue your research

What OSEL Devices Ltd's management said in earlier quarters

  • Q4 FY25 earnings call analysis →
  • Q2 FY26 earnings call analysis →

Others in Healthcare Equipment & Supplies this season

  • Prevest Denpro Ltd (Q1 FY27)

    Digital dentistry revenue, especially 3D printing resins, grew 40% this year; 3D printer sales rose by 162%, indicating strong growth potential, with plans for…

  • Vasa Denticity Ltd (Q1 FY27)

    Average order value increased by about 27% largely due to higher ticket-size products; order volume growth was around 8% (Page 6). Key concall takeaways from…

  • Poly Medicure (Q1 FY27)

    Europe and Southeast Asia markets are key growth drivers currently, with Europe showing 17%+ growth in Q1. Key concall takeaways from Poly Medicure's Q1 FY27…

  • Tarsons Products (Q1 FY27)

    Cash profitability grew 18% YoY in Q1 FY’27, showing underlying strength; profits remain moderate in FY’27 due to higher depreciation and interest but will…

Compare:vs Poly Medicurevs Fischer Medicalvs Tarsons Products